EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

[1]  M. Weller,et al.  Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  David T. W. Jones,et al.  Infratentorial IDH-mutant astrocytoma is a distinct subtype , 2020, Acta Neuropathologica.

[3]  K. Aldape,et al.  Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. J. van den Bent,et al.  Determining medical decision-making capacity in brain tumor patients: why and how? , 2020, Neuro-oncology practice.

[5]  M. Weller,et al.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.

[6]  D. Berry,et al.  GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. , 2020, Journal of Clinical Oncology.

[7]  M. Weller,et al.  How did lomustine become standard of care in recurrent glioblastoma? , 2020, Cancer treatment reviews.

[8]  J. Olson,et al.  Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification , 2020, Cancer.

[9]  C. Balañà,et al.  A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01). , 2020, Neuro-oncology.

[10]  Raymond Y Huang,et al.  Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. , 2020, Neuro-oncology.

[11]  Pieter Wesseling,et al.  cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading , 2020, Brain pathology.

[12]  Raymond Y Huang,et al.  Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.

[13]  M. Weller,et al.  Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. , 2020, Cancer letters.

[14]  G. Reifenberger,et al.  Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma. , 2020, Neuro-oncology.

[15]  Jennie W. Taylor,et al.  Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. , 2020, JAMA oncology.

[16]  E. Shaw,et al.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma. , 2020, Neuro-oncology.

[17]  G. Reifenberger,et al.  cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas , 2020, Acta Neuropathologica.

[18]  Brett E. Youngerman,et al.  Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy for Epilepsy: Systematic Review of Technique, Indications, and Outcomes. , 2020, Neurosurgery.

[19]  M. Taphoorn,et al.  Prediagnostic symptoms and signs of adult glioma: the patients’ view , 2020, Journal of Neuro-Oncology.

[20]  M. Mehta,et al.  ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA , 2019, Neuro-Oncology.

[21]  E. Migliore,et al.  Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016 , 2019, Journal of Neuro-Oncology.

[22]  W. Mason,et al.  ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION , 2019, Neuro-Oncology.

[23]  David T. W. Jones,et al.  Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities , 2019, Acta Neuropathologica Communications.

[24]  M. J. van den Bent,et al.  Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. , 2019, Neuro-oncology.

[25]  A. Mahajan,et al.  Carbon ion radiotherapy in the treatment of gliomas: a review , 2019, Journal of Neuro-Oncology.

[26]  E. Migliore,et al.  Correction to: Efficacy of initial temozolomide for high‑risk low grade gliomas in a phase II AINO (Italian Association for Neuro‑Oncology) study: a post‑hoc analysis within molecular subgroups of WHO 2016 , 2019, Journal of Neuro-Oncology.

[27]  K. Aldape,et al.  PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion , 2019, Neuro-Oncology.

[28]  F. Ducray,et al.  PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas , 2019, Neuro-Oncology.

[29]  M. Ruge,et al.  Frame-based stereotactic biopsy of deep-seated and midline structures in 511 procedures: feasibility, risk profile, and diagnostic yield , 2019, Acta Neurochirurgica.

[30]  F. Ducray,et al.  CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. , 2019, Neuro-oncology.

[31]  G. Widhalm,et al.  In Reply: Is Intraoperative Pathology Needed if 5-Aminolevulinic-Acid-Induced Tissue Fluorescence Is Found in Stereotactic Brain Tumor Biopsy? , 2019, Neurosurgery.

[32]  N. Sunaga,et al.  An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer , 2019, AntiCancer Research.

[33]  Martin Glas,et al.  Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial , 2019, The Lancet.

[34]  Donald H. Lee,et al.  Radiology reporting of low-grade glioma growth underestimates tumor expansion , 2019, Acta Neurochirurgica.

[35]  M. Argyropoulou,et al.  Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas , 2018, Contrast media & molecular imaging.

[36]  David M. Hyman,et al.  BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Reifenberger,et al.  cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” , 2018, Acta Neuropathologica.

[38]  M. J. van den Bent,et al.  Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. , 2018, The Lancet Oncology.

[39]  L. Held,et al.  Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  J. Huse,et al.  Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas , 2018, Journal of neuropathology and experimental neurology.

[41]  David T. W. Jones,et al.  Novel, improved grading system(s) for IDH-mutant astrocytic gliomas , 2018, Acta Neuropathologica.

[42]  Thomas C. Chen,et al.  Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial , 2018, JAMA oncology.

[43]  M. Weller.  Where does O6‐methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma? , 2018, Cancer.

[44]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[45]  F. Lieberman,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.

[46]  Martin Klein,et al.  Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.

[47]  M. J. van den Bent,et al.  The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis , 2017, Neuro-oncology.

[48]  D. Brachman,et al.  Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study , 2017, The Lancet.

[49]  Act Investigators.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial , 2017 .

[50]  J. Simes,et al.  Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial. , 2017, Neuro-oncology practice.

[51]  B. Rasmussen,et al.  Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry , 2017, Journal of Neuro-Oncology.

[52]  M. J. van den Bent,et al.  EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  G. Reifenberger,et al.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.

[54]  M. Weller,et al.  European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. , 2017, The Lancet. Oncology.

[55]  S. Torp,et al.  Surgical resection versus watchful waiting in low-grade gliomas , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  D. Osoba,et al.  Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma , 2017, The New England journal of medicine.

[57]  Guido Reifenberger,et al.  Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel , 2017, Brain pathology.

[58]  Benjamin M. Ellingson,et al.  Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials , 2017, Neurotherapeutics.

[59]  A. Brodbelt,et al.  Surgeon volume and 30 day mortality for brain tumours in England , 2016, British Journal of Cancer.

[60]  Brigitta G. Baumert,et al.  Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma , 2016, The Lancet. Oncology.

[61]  Ian Law,et al.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.

[62]  Susan M. Chang,et al.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide , 2016, Neuro-oncology.

[63]  A. Sahgal,et al.  External beam radiation dose escalation for high grade glioma. , 2016, The Cochrane database of systematic reviews.

[64]  F. Ducray,et al.  The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. , 2016, Neuro-oncology.

[65]  J. Debus,et al.  Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma , 2016, Strahlentherapie und Onkologie.

[66]  T. Huber,et al.  Patterns and Time Dependence of Unspecific Enhancement in Postoperative Magnetic Resonance Imaging After Glioblastoma Resection. , 2016, World neurosurgery.

[67]  Stefan M. Pfister,et al.  Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets , 2016, Acta Neuropathologica.

[68]  Mauro Delorenzi,et al.  Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. , 2016, The Journal of molecular diagnostics : JMD.

[69]  R. Stupp,et al.  Corticosteroids compromise survival in glioblastoma. , 2016, Brain : a journal of neurology.

[70]  Walter J. Curran,et al.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. , 2016, The New England journal of medicine.

[71]  W. Wick.  TTFields: where does all the skepticism come from? , 2016, Neuro-oncology.

[72]  G. Reifenberger,et al.  Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. , 2015, Neuro-oncology.

[73]  J. Barnholtz-Sloan,et al.  Understanding inherited genetic risk of adult glioma - a review. , 2015, Neuro-oncology practice.

[74]  T. Cloughesy,et al.  NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI) , 2015 .

[75]  B. Jeremic,et al.  International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Marion Smits,et al.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. , 2015, Neuro-oncology.

[77]  Volker Hovestadt,et al.  Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities , 2015, Acta Neuropathologica.

[78]  G. Reifenberger,et al.  Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. , 2015, Neuro-oncology.

[79]  G. Reifenberger,et al.  MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial , 2015, Clinical Cancer Research.

[80]  T. Kauko,et al.  Presenting symptoms of glioma in adults , 2015, Acta neurologica Scandinavica.

[81]  M. Gjerris,et al.  Primo non nocere or maximum survival in grade 2 gliomas? A medical ethical question , 2015, Acta Neurochirurgica.

[82]  Amy S Nowacki,et al.  Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. , 2014, Journal of neurosurgery.

[83]  M. Mehta,et al.  The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria , 2014, Neuro-oncology.

[84]  M. Gilbert,et al.  Bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[85]  Armin Giese,et al.  Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients , 2014, Acta Neurochirurgica.

[86]  D. Brat,et al.  The role of radiotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. , 2014 .

[87]  J. Olson,et al.  The role of radiotherapy in the management of progressive glioblastoma , 2014, Journal of Neuro-Oncology.

[88]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[89]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[90]  Walter J Curran,et al.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  G. Reifenberger,et al.  Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation , 2013, Neurology.

[92]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[95]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[96]  J. Baehring,et al.  Faculty Opinions recommendation of NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012 .

[97]  P. Gutin,et al.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012, European journal of cancer.

[98]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[99]  M. Berger,et al.  Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[101]  A. Jakola,et al.  The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. , 2011, World neurosurgery.

[102]  M. Brainin,et al.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004 * , 2004, European journal of neurology.

[103]  L Junck,et al.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. , 2011, The Lancet. Oncology.

[104]  K. Hopkins,et al.  Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Thomas Benner,et al.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  W. Mason,et al.  Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  L. Senelick.  It (review) , 2008 .

[112]  H. Heinzl,et al.  Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.

[113]  G. Reifenberger,et al.  Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas , 2007, International journal of cancer.

[114]  Luc Taillandier,et al.  Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.

[115]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[116]  M. Piérart,et al.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial , 2005, The Lancet.

[117]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[118]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[119]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[120]  M. Brainin,et al.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2012 , 2004, European journal of neurology.

[121]  M. Brainin,et al.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004 * , 2004 .

[122]  E. Bruera,et al.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  Z. Ram,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[124]  M. Brainin,et al.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces , 2001, European journal of neurology.

[125]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[127]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[128]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[129]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. , 2019, Neuro-oncology.

[130]  Stefan M. Pfister,et al.  Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions , 2019, Acta Neuropathologica.

[131]  J. Furtner,et al.  Is Intraoperative Pathology Needed if 5-Aminolevulinic-Acid-Induced Tissue Fluorescence Is Found in Stereotactic Brain Tumor Biopsy? , 2019, Neurosurgery.

[132]  F. Kreth,et al.  Brachytherapy of Intracranial Gliomas. , 2018, Progress in neurological surgery.

[133]  L. Recht,et al.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. , 2017, The Lancet. Oncology.

[134]  Eilon D. Kirson,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma , 2017 .

[135]  Claus Belka,et al.  ESTRO-ACROP guideline "target delineation of glioblastomas". , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[136]  S. Heiland,et al.  Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. , 2015, Neuro-oncology.

[137]  K. Aldape,et al.  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. , 2014, Neuro-oncology.

[138]  K. Hoang-Xuan,et al.  Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors , 2013, Journal of Neuro-Oncology.

[139]  G. Beldi,et al.  A prospective, randomized clinical trial , 2004 .

[140]  J. Jääskeläinen,et al.  Debulking or biopsy of malignant glioma in elderly people – a randomised study , 2003, Acta Neurochirurgica.

[141]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. , 1995, Lancet.

[142]  K. Whitehorn,et al.  The Patients’ View , 1991 .

[143]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.